Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 5Gastrointestinal 3Breast 3Thoracic 2Plasma cell 2Tumor-Agnostic 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Endocrine 1

Conditions

Vomiting 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 510Cisplatin 410Pemetrexed 400Radiotherapy 285Docetaxel 244Paclitaxel 227pembrolizumab 226Gemcitabine 198Drug Therapy 191Bevacizumab 190Erlotinib Hydrochloride 189Radiosurgery 177Nivolumab 168Etoposide 155durvalumab 154osimertinib 126atezolizumab 109Gefitinib 96Blood Specimen Collection 93Magnetic Resonance Spectroscopy 91Vinorelbine 90anlotinib 88Surgical Procedures, Operative 85Ipilimumab 62Immunotherapy 62Surveys and Questionnaires 60sintilimab 59Specimen Handling 59tislelizumab 58Irinotecan 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Olanzapine × Thoracic × Clear all
NCT06554613 2026-05-05

Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC

Second Affiliated Hospital of Nanchang University

Phase 2 Recruiting
156 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03571126 2021-07-13

Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer

Zunyi Medical College

Phase 4 Unknown
156 enrolled
Thoracic

Lung Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡